R-Tech Ueno


News

News List RSS

May 29, 2015

Presentation Video for the Analyst Meeting (for FY 3/2015) dated of May 21, 2015.
* When the above-mentioned page is not displayed, please have a look by You Tube.

May 25, 2015

Announcement on Completion of the Phase I Single-Dose Clinical Trial for the novel VAP-1 Inhibitor RTU-1096

May 18, 2015

Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

May 18, 2015 "Potentials to Expand Region-Wise" Fiscal Year March 2015 Earnings Results WRJ Flash Report: IR report issued by Walden Research Japan Incorporated.

May 14, 2015

R-Tech Ueno Announces Fiscal Year March 2015 Earnings

May 14, 2015 Summary of Business Results for the Year Ended March 31, 2015 [Japan GAAP] (Non-consolidated)

May 13, 2015

Sucampo and Harbin Gloria Pharmaceuticals Enter Into Licensing Agreement for AMITIZA® (lubiprostone) in China

May 8, 2015

Presentations of two studies on Unoprostone (development code UF-021) for retinitis pigmentosa announced at The Association for Research in Vision and Ophthalmology 2015

May 7, 2015

Termination of License Agreements for Unoprostone

April 27, 2015

Announcement on Acquisition of the Right to Develop and Commercialize DE-105 from Santen Pharmaceutical Co., Ltd.

April 14, 2015

Announcement on determination of the selling price etc.

April 6, 2015

Announcement on secondary offering of shares and changes of the controlling shareholder except for the parent company and other affiliates

April 1, 2015

Commission of a visiting Professor from Keio University

Stock Performance

University Collaborative Research

Our Products

R-Tech Ueno's originally developed Rescula® Eye Drops is a glaucoma/ocular hypertension treatment drug that was the first in the world to utilize Prostone.


Brief

IR E-mail

FAQ

Contact Us


Head Office: NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, Japan

Page Top